Sequana Medical Announces the Completion of alfapump Implantations in POSEIDON, the North American Pivotal alfapump Study morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.
Reporting of primary endpoint on track for Q4 2022FDA regulatory submission on track for mid-202370% survival of POSEIDON Roll-In patients at one year post-implantation1 compares favourably
Reporting of primary endpoint on track for Q4 2022FDA regulatory submission on track for mid-202370% survival of POSEIDON Roll-In patients at one year.
Reporting of primary endpoint on track for Q4 2022FDA regulatory submission on track for mid-202370% survival of POSEIDON Roll-In patients at one year.